SON-1010: A New Cancer Treatment Using IL-12
Author Information
Author(s): Cini John K., Kenney Richard T., Dexter Susan, McAndrew Stephen J., Eraslan Rukiye-Nazan, Brody Rich, Rezac Darrel J., Boohaker Rebecca, Lapi Suzanne E., Mohan Pankaj
Primary Institution: Sonnet BioTherapeutics, Inc.
Hypothesis
Can an albumin-binding IL-12 fusion protein improve cytokine half-life, target tumors, and enhance therapeutic efficacy?
Conclusion
SON-1010 effectively targets tumors and has a prolonged half-life, enhancing its therapeutic efficacy.
Supporting Evidence
- SON-1010 showed a 4-fold increase in half-life compared to standard IL-12.
- Significant tumor growth inhibition was observed in treated mice.
- SON-1010 demonstrated enhanced immune response with increased IFNγ production.
- Safety and efficacy are being studied in ongoing clinical trials.
Takeaway
Scientists created a new medicine called SON-1010 that helps fight cancer by making a special protein last longer in the body and go directly to the tumors.
Methodology
The study involved developing a fusion protein that links IL-12 to an albumin-binding domain, followed by preclinical testing in mouse models.
Potential Biases
Potential bias due to funding from Sonnet BioTherapeutics, Inc.
Limitations
The study primarily focused on mouse models, which may not fully predict human responses.
Participant Demographics
C57BL/6 female mice were used in the study.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website